Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report, Clin Oncol Case Rep Vol: 4 Issue: 12

Systemic Treatment for Patients with HER2-Positive Breast Cancer and Brain Metastases

Wing-Lok Chan*

Department of Clinical Oncology, LKS, The University of Hong Kong, Hong Kong

*Corresponding Author : Wing-Lok Chan
Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, 1/F Professorial Block, Queen Mary Hospital, Hong Kong
Tel: 852-22553111
E-mail: [email protected]

Received: September 03, 2021 Accepted: December 11, 2021 Published: December 25, 2021

Citation: Chan WL (2021) Systemic Treatment for Patients with HER2-Positive Breast Cancer and Brain Metastases. Clin Oncol Case Rep 4:12.

Abstract

There is no consensus on the treatment of brain metastases in patients with HER2-positive breast cancer. This article reported a patient attained long intracranial control and survival with the use of multiple anti-HER2 agents. Treatment of brain metastases in patients with HER2-positive breast cancer should involve both local therapies and systemic anti-HER2 agents. Radiotherapy and surgery can disrupt the blood-brain barrier. This, in turn, allows the larger molecules like trastuzumab and pertuzumab to penetrate through for better control in the brain metastases. Novel anti-HER2 agents including lapatinib, neratinib, trastuzumab emtansine (TDM1), trastuzumab deruxtecan (T-DXd) can penetrate the bloodbrain barrier and can attain significant improvement in the response of the brain metastases.

Keywords: Breast cancer; Brain metastases; Pertuzumab; Trastuzumab; Neratinib

Track Your Manuscript

Recommended Conferences

4th World Congress on Women Oncology & Care

Bangkok, Thailand

44th Euro-Global Summit on Cancer Therapy & Radiation Oncology

London, United Kingdom

World congress and Expo on Diabetes

Manila, Philippines

open access